Top 3 drug approvals in oncology in March 2022: Sotorasib, Opdualag™ and Pluvicto™

As we eagerly await presentations and the exciting data sure to be presented at the the AACR 2022 Annual Meeting (8–13 April, LA, USA), we are looking back at what drugs have been approved this past month for various cancer indications. Read about two US FDA approvals as well as an approval from across the pond in the UK. Lumykras® (sotorasib) Approved: 3 March 2022 Approving body: National Institute for Health and Care Excellence (NICE) Indication: KRAS G12C locally advanced or metastatic NSCLC To kickstart the month, sotorasib  was recommended by NICE (UK) - for use through the Cancer Drugs Fund...